Daily Stock Analysis, AQXP, Aquinox Pharmaceuticals Inc, priceseries

Aquinox Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
11.15
Close
11.61
High
11.79
Low
11.12
Previous Close
11.23
Daily Price Gain
0.38
YTD High
18.13
YTD High Date
Jun 23, 2020
YTD Low
5.81
YTD Low Date
Mar 16, 2020
YTD Price Change
-0.24
YTD Gain
-2.03%
52 Week High
18.13
52 Week High Date
Jun 23, 2020
52 Week Low
2.53
52 Week Low Date
Oct 21, 2019
52 Week Price Change
8.76
52 Week Gain
307.37%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
May 30. 2018
13.25
Jun 8. 2018
14.19
7 Trading Days
7.13%
Link
LONG
Aug 7. 2019
3.28
Aug 21. 2019
3.59
10 Trading Days
9.56%
Link
LONG
Sep 10. 2019
3.11
Sep 19. 2019
3.39
7 Trading Days
8.87%
Link
LONG
Nov 18. 2019
3.00
Dec 5. 2019
4.51
12 Trading Days
50.23%
Link
LONG
Dec 9. 2019
6.28
Jan 3. 2020
10.80
17 Trading Days
71.97%
Link
LONG
Jan 27. 2020
11.06
Feb 10. 2020
12.26
10 Trading Days
10.88%
Link
LONG
Mar 20. 2020
8.03
Apr 3. 2020
10.16
10 Trading Days
26.58%
Link
LONG
Apr 8. 2020
10.59
Apr 23. 2020
12.82
10 Trading Days
21.06%
Link
LONG
Jun 16. 2020
13.29
Jun 26. 2020
15.63
8 Trading Days
17.57%
Link
LONG
Aug 5. 2020
10.62
Aug 24. 2020
12.05
13 Trading Days
13.45%
Link
Company Information
Stock Symbol
AQXP
Exchange
NasdaqGM
Company URL
http://www.aqxpharma.com
Company Phone
604-629-9223
CEO
David J. Main
Headquarters
British Columbia
Business Address
887 GREAT NORTHERN WAY, SUITE 450, VANCOUVER, CANADA V5T 4T5
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001404644
About

Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops targeted therapeutics for inflammation and immuno-oncology. The company's primary focus is on anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox Pharmaceuticals was founded by Raymond J. Andersen, David J. Main, Low Fung Mui, Christopher John Ong and Gerald Krysta on December 26, 2003 and is headquartered in Vancouver, Canada.

Description

Aquinox Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The company primarily focuses on anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1 (SHIP1) enzyme, a key regulator of a cellular signaling pathway in immune cells. Its lead product candidate is AQX-1125, a small molecule activator of SHIP1 that is in Phase III clinical trials for treatment in interstitial cystitis/bladder pain syndrome, a chronic inflammatory disease of the bladder. The company was founded in 2003 and is headquartered in Vancouver, Canada.